Prime Medicine, Inc.
Financials
Valuation Metrics
Prime Medicine, Inc.'s Market Cap is $564M. At end of 2025 it was $516M. Ranked #2749 of 3,121 in US market (top 88%), #1191 of 1,463 on NASDAQ (top 81%), #220 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 83%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $564M | US#2,749/3,121 Sec#220/266 |
| Revenue | $4M | US#2,856/3,121 Sec#182/266 |
| Net Income | $-188M | US—/3,121 Sec—/266 |
| Total Assets | $249M | US#2,958/3,121 Sec#231/266 |
| Net Assets | $40M | US#2,876/3,121 Sec#228/266 |
| Employees | 146 | US#2,554/3,121 Sec#147/266 |
| Value | ||
| P/B | 14.16x | US#2,722/3,121 Sec#205/266 |
| P/S | 138.36x | US#2,958/3,121 Sec#185/266 |
| FCF Yield | -27.83% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROA | -75.45% | US#3,042/3,121 Sec#244/266 |
| Op. Margin | -4824.94% | US#2,859/3,121 Sec#180/266 |
| Revenue Growth | -17.90% | US#2,678/3,121 Sec#152/266 |
| Financial Health | ||
| Debt Ratio | 525.59% | US#2,382/3,121 Sec#225/266 |
| Total Debt | $112M | US#2,411/3,121 Sec#114/266 |
| FCF | $-157M | US#2,728/3,121 Sec#182/266 |
| Cash | $47M | US#2,601/3,121 Sec#231/266 |
| Current Ratio | 3.05x | US#774/3,121 Sec#190/266 |
| Performance | ||
| 1Y Return | -39.06% | US#2,675/3,121 Sec#228/266 |
| 1M Return | -11.86% | US#633/3,121 Sec#65/266 |
| From 52W High | -55.04% | US#2,829/3,121 Sec#225/266 |
| 1Y MDD | -59.52% | US#2,769/3,121 Sec#213/266 |
| Trading | ||
| Volume | 4,295,335 shares | US#532/3,121 Sec#45/266 |
| Trading Value | $13M | US#2,325/3,121 Sec#191/266 |
| Per Share | ||
| EPS | $-1.04 | US—/3,121 Sec—/266 |
| BPS | $0.22 | US#2,791/3,121 Sec#229/266 |
Company Info
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.